Brought to you by 
Series B round of $85mm is raised for Solstice Neurosciences
04 Dec 2006
Executive Summary
Specialty pharma Solstice Neurosciences, marketer of the cervical dystonia product Myobloc/NeuroBloc, grossed $85mm in a Series B round combining equity and debt. Lead investor Highland Capital Management was joined by returning Series A backers Thomas, McNerney & Partners, Investor Growth Capital, Morgan Stanley Venture Partners, and Oxford Bioscience Partners. Two representatives from Highland join the company's board. Aquilo Partners acted as the placement agent.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B round of $85mm is raised for Solstice Neurosciences
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice